|
|
|
|
| Looking for a U.S. based CRO or CDMO? Curia’s 10 U.S. facilities and 30+ year track record can support your small molecule or biologic from curiosity to cure. Whether you’re a small startup with a big idea or an established sponsor seeking additional capacity, Curia can support your discovery, development, or manufacturing needs. Learn more. |
|
|
|
|
Getting To The Heart Of CDMO Tech Transfer Excellence | Article | Bora Pharmaceuticals | Uncover five key factors that drive a seamless and efficient technology transfer, highlighting how a culture of technical expertise, customer focus, and operational flexibility is crucial to success. |
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | With a tinge of trepidation at being thought of as whimsical, I asked our Editorial Advisory Board: Can consideration of a CDMO’s passion play a role in due diligence for selecting a partner? Is there a qualifiable measurement (intuition?) related to a CDMO’s enthusiasm? I was surprised (and relieved) by the, well, passion with which some Board members replied. Here's what they think. | |
|
|
Process Validation: Harmonization Of Terms Used To Identify Validation Lots | By Humberto Vega, Ph.D., former global head MS&T at JnJ and BMS, Robert Dream, Nivagen Pharmaceuticals, Inc., and Igor Gorsky, Valsource | The terms “confirmatory" and "conformance" batches are inconsistently used in the industry. Since process validation is essential for maintaining compliance and detecting variability, we must work toward harmonization of the terms to avoid confusion. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
A Roadmap To Expedited Review Pathways | Article | Qotient Sciences | Accelerated development and manufacturing timelines provide developers with paths to move new therapies to market quickly while still maintaining a balance of risk/benefit assessment. |
|
|
|
Solutions For Accelerated Pharmaceutical Development | Article | By David K. Lyon, Ph.D. and Conrad Roten, Ph.D., Lonza | Explore an integrated service package designed to simplify and accelerate the development pathway, even for APIs with challenging properties such as low aqueous solubility and poor bioavailability. |
|
|
|
Cambrex Scientist Spotlight: Luigi Bellone | Cambrex | Luigi Bellone, Head of Quality Assurance in Paullo, Milan, brings over 20 years of experience in quality assurance (QA), quality control (QC), and regulatory compliance within the pharmaceutical industry. |
|
|
Capabilities Update October 2025: Fill/Finish | medac CDMO | Find more than just reliable, flexible support along the entire value chain of injectables. Learn how dual-site EU-based operations provide scalable capacity and seamless global supply for your molecules. |
|
|
OPCU April 2025: Small Molecule | SK pharmteco | Join Nicholas Duda, Executive Director of Business Development, as he highlights our available capacity across North America, Europe, and Asia, and our unique capabilities. |
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|